Present and future costs of COPD in Iceland and Norway: Results from the BOLD study

European Respiratory Journal

Volumn 34, Issue 4, 2009, Pages 850-857

  Nielsen, R ^a,b   Johannessen, A ^b   Benediktsdottir, B ^c   Gislason, T ^c   Buist, A S ^d   Gulsvik, A ^a,b   Sullivane, S D ^e   Lee, T A ^f,g  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF ICELAND   (Iceland)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HINES VA HOSPITAL   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Computer simulation; Cost of illness; Disease progression; Iceland; Markov chains; Norway

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER SIMULATION; DISEASE EXACERBATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MALE; NORWAY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS;

BUDGETS; COMPUTER SIMULATION; COST OF ILLNESS; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; ICELAND; MARKOV CHAINS; MODELS, ECONOMETRIC; NORWAY; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 70349646763     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00166108     Document Type: Article

References (41)

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750. (Pubitemid 47321907)
2. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122: 1994-2002. (Pubitemid 36051135)
3. Bilde L, Rud Svenning A, Dollerup J, et al. The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls. Respir Med 2007; 101: 539-546. (Pubitemid 46196322)
4. Jacobson L, Hertzman P, Lofdahl CG, et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94: 247-255.
5. Ward MM, Javitz HS, Smith WM, et al. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 2000; 94: 1123-1129.
6. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000; 94: 204-213. (Pubitemid 30198069)
7. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more transferable? Eur J Health Econ 2005; 6: 334-346.
8. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7: 153-167. (Pubitemid 38420728)
9. Hoogendoorn MM, Rutten-van Mölken MP, Hoogenveen RRT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26: 223-233. (Pubitemid 41079065)
10. Oostenbrink JB, Rutten-van Mölken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32-46.
11. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116: 325-331. (Pubitemid 38230292)
12. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
13. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005; 2: 277-283.
14. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of COPD - 2006 Update. Am J Respir Crit Care Med 2007; 176: 532-555.
15. Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 630-634. (Pubitemid 44411632)
16. Lee TA, Gao C-Y, Walter B, et al. Rate of disease progression in patients with COPD in the Framingham Heart Study cohort. Chest Meeting Abstracts 2006; 130: 97S.
17. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179-187. (Pubitemid 29036522)
19. Statistics Norway. Table 03026: Population, by sex and one year age groups. http://statbank.ssb.no//statistikkbanken/default-fr. asp?PLanguage51 Date last accessed: September 23, 2008.
20. Bakke PS, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991; 46: 863-870.
21. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409. (Pubitemid 28140699)
22. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-393. (Pubitemid 36560940)
23. WHO Statistical Information System (WHOSIS). WHO Mortality Database. www.who.int/whosis/mort/download/en/index.html Date last accessed: September 22, 2008.
24. Johannessen A, Omenaas E, Bakke P, et al. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis 2005; 9: 926-932. (Pubitemid 41139654)
25. Statistics Norway. www.ssb.no Date last accessed: March 16, 2008.
26. Statistics Iceland. www.statice.is Date last accessed: March 16, 2008.
27. Samet JM. The 1990 report of the Surgeon General: the health benefits of smoking cessation. Am Rev Respir Dis 1990; 142: 993-994.
28. CDC. Smoking cessation during previous year among adults - United States, 1990 and 1991. MMWR 1993; 42: 504-507.
29. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708.
30. Norges Bank. www.norges-bank.no/Pages/Article-41230.aspx Date last accessed: March 16, 2008.
31. The Central Bank of Iceland. www.sedlabanki.is/?PageID5183 Date last accessed: March 16, 2008.
32. Statistics Iceland. General government total expenditure in details by functions 1998-2006. http://statice.is/?PageID51269&src5/temp- en/Dialog/varval.asp?ma5THJ05142%26ti5General+government+ total+expenditure+in+details+by+functions+1998%2D2006%26path 5./Database/thjodhagsreikningar/fjarmal-opinber/%26lang5 1%26units5Million%20ISK/percent Date last accessed: August 25, 2008.
33. Statistics Norway. System of Health Accounts, 1997-2007. www. ssb.no/english/subjects/09/01/helsesat-en/ Date last accessed: August 25, 2008.
34. Eagan TM, Eide GE, Gulsvik A, et al. Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol 2002; 55: 775-781.
35. Feenstra TL, van Genugten ML, Hoogenveen RT, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-596.
36. Wouters EFM. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97: S3-S14. (Pubitemid 36266865)
37. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
38. Johannessen A, Lehmann S, Omenaas ER, et al. Post-broncho-dilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006; 173: 1316-1325. (Pubitemid 43900705)
39. Janson C, Gislason T, Suppli U, et al. Characteristics of hospitalised patients with COPD in the Nordic countries. Respir Med 2006; 100: S10-S16. (Pubitemid 44752638)
40. Organisation for economic co-operation and development (OECD). Purchasing Power Parities (PPP).www.oecd.org/std/ppp Date last accessed: January 2, 2009.
41. Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics 1999; 15: 241-256.